At the time of writing, Standard BioTools Inc [LAB] stock is trading at $1.29, up 0.78%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The LAB shares have gain 7.50% over the last week, with a monthly amount drifted -6.52%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on August 13, 2025, when TD Cowen downgraded its rating to a Hold but kept the price target unchanged to $1.55 for it. Previously, KeyBanc Capital Markets downgraded its rating to Sector Weight on February 27, 2025. On April 16, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $3.25 on April 04, 2024. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $4 as its price target on July 12, 2023.
For the past year, the stock price of Standard BioTools Inc fluctuated between $0.92 and $2.32. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $1.29 at the most recent close of the market. An investor can expect a potential return of 151.94% based on the average LAB price forecast.
Analyzing the LAB fundamentals
According to Standard BioTools Inc [NASDAQ:LAB], the company’s sales were 154.24M for trailing twelve months, which represents an -41.51% plunge. Gross Profit Margin for this corporation currently stands at 0.43% with Operating Profit Margin at -0.76%, Pretax Profit Margin comes in at -0.66%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.26 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.2633 points at the first support level, and at 1.2367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3083, and for the 2nd resistance point, it is at 1.3267.
Ratios To Look Out For
It is important to note that Standard BioTools Inc [NASDAQ:LAB] has a current ratio of 5.16. Further, the Quick Ratio stands at 4.92, while the Cash Ratio is 1.62. Considering the valuation of this stock, the price to sales ratio is 3.19, the price to book ratio is 1.16.
Transactions by insiders
Recent insider trading involved Casdin Partners Master Fund, L, Director, that happened on Aug 22 ’25 when 0.2 million shares were purchased. Director, Casdin Partners Master Fund, L completed a deal on Aug 25 ’25 to buy 0.2 million shares. Meanwhile, Director Casdin Partners Master Fund, L bought 0.12 million shares on Aug 26 ’25.
